<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">BMC Pregnancy Childbirth</journal-id>
<journal-id journal-id-type="iso-abbrev">BMC Pregnancy Childbirth</journal-id>
<journal-title-group>
<journal-title>BMC Pregnancy and Childbirth</journal-title>
</journal-title-group>
<issn pub-type="epub">1471-2393</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30621627</article-id>
<article-id pub-id-type="pmc">6323705</article-id>
<article-id pub-id-type="publisher-id">2152</article-id>
<article-id pub-id-type="doi">10.1186/s12884-018-2152-z</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Non-additive effects of ACVR2A in preeclampsia in a Philippine population</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name>
<surname>Amosco</surname>
<given-names>Melissa D.</given-names>
</name>
<address>
<email>mdamosco@up.edu.ph</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Tavera</surname>
<given-names>Gloria R.</given-names>
</name>
<address>
<email>gloria.tavera@case.edu</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Villar</surname>
<given-names>Van Anthony M.</given-names>
</name>
<address>
<email>vvillar@email.gwu.edu</email>
</address>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Naniong</surname>
<given-names>Justin Michael A.</given-names>
</name>
<address>
<email>jananiong@mbb.upd.edu.ph</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>David-Bustamante</surname>
<given-names>Lara Marie G.</given-names>
</name>
<address>
<email>laraob@yahoo.com</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Williams</surname>
<given-names>Scott M.</given-names>
</name>
<address>
<email>smw154@case.edu</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jose</surname>
<given-names>Pedro A.</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Palmes-Saloma</surname>
<given-names>Cynthia P.</given-names>
</name>
<address>
<email>cpsaloma@up.edu.ph</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9950 521X</institution-id><institution-id institution-id-type="GRID">grid.443239.b</institution-id><institution>National Institute of Molecular Biology and Biotechnology, National Science Complex, University of the Philippines, Diliman, </institution></institution-wrap>1101 Quezon City, Philippines </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0367 254X</institution-id><institution-id institution-id-type="GRID">grid.417272.5</institution-id><institution>Department of Obstetrics and Gynecology, </institution><institution>Philippine General Hospital - University of the Philippines, </institution></institution-wrap>Taft Avenue, 1000 Manila, Philippines </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2164 3847</institution-id><institution-id institution-id-type="GRID">grid.67105.35</institution-id><institution>Department of Population and Quantitative Health Sciences, </institution><institution>Case Western Reserve University, School of Medicine, </institution></institution-wrap>Cleveland, OH 44106 USA </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9510</institution-id><institution-id institution-id-type="GRID">grid.253615.6</institution-id><institution>Division of Renal Diseases &amp; Hypertension, Department of Medicine, </institution><institution>The George Washington University of School of Medicine &amp; Health Sciences, </institution></institution-wrap>Washington, DC, 20037 USA </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9510</institution-id><institution-id institution-id-type="GRID">grid.253615.6</institution-id><institution>Department of Pharmacology and Physiology, </institution><institution>The George Washington University of School of Medicine &amp; Health Sciences, </institution></institution-wrap>Washington, DC, 20037 USA </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0636 6193</institution-id><institution-id institution-id-type="GRID">grid.11134.36</institution-id><institution>Philippine Genome Center, National Science Complex, </institution><institution>University of the Philippines, Diliman, </institution></institution-wrap>1101 Quezon City, Philippines </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>8</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>8</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>19</volume>
<elocation-id>11</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>12</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p id="Par1">Multiple interrelated pathways contribute to the pathogenesis of preeclampsia, and variants in susceptibility genes may play a role among Filipinos, an ethnically distinct group with high prevalence of the disease. The objective of this study was to examine the association between variants in maternal candidate genes and the development of preeclampsia in a Philippine population.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">A case-control study involving 29 single nucleotide polymorphisms (SNPs) in 21 candidate genes was conducted in 150 patients with preeclampsia (cases) and 175 women with uncomplicated normal pregnancies (controls). Genotyping for the <italic>GRK4</italic> and <italic>DRD1</italic> gene variants was carried out using the TaqMan Assay, and all other variants were assayed using the Sequenom MassARRAY Iplex Platform. PLINK was used for SNP association testing. Multilocus association analysis was performed using multifactor dimensionality reduction (MDR) analysis.</p>
</sec>
<sec>
<title>Results</title>
<p id="Par3">Among the clinical factors, older age (<italic>P</italic> &lt;  1 × 10–4), higher BMI (<italic>P</italic> &lt;  1 × 10–4), having a new partner (<italic>P</italic> = 0.006), and increased time interval from previous pregnancy (<italic>P</italic> = 0.018) associated with preeclampsia. The MDR algorithm identified the genetic variant <italic>ACVR2A</italic> rs1014064 as interacting with age and BMI in association with preeclampsia among Filipino women.</p>
</sec>
<sec>
<title>Conclusions</title>
<p id="Par4">The MDR algorithm identified an interaction between age, BMI and <italic>ACVR2A</italic> rs1014064, indicating that context among genetic variants and demographic/clinical factors may be crucial to understanding the pathogenesis of preeclampsia among Filipino women.</p>
</sec>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (10.1186/s12884-018-2152-z) contains supplementary material, which is available to authorized users.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Association study</kwd>
<kwd>Multifactor dimensionality reduction</kwd>
<kwd>Philippines</kwd>
<kwd>Preeclampsia</kwd>
<kwd>Single nucleotide polymorphism</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>University of the Philippines Emerging Interdisciplinary Research (EIDR) Program</institution>
</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100003172</institution-id>
<institution>National Kidney Foundation of Maryland</institution>
</institution-wrap>
</funding-source>
<award-id>minigrant</award-id>
<principal-award-recipient>
<name>
<surname>Villar</surname>
<given-names>Van Anthony M.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id>
<institution>National Institutes of Health</institution>
</institution-wrap>
</funding-source>
<award-id>R37HL023081</award-id>
<award-id>TL1 TR000441</award-id>
<principal-award-recipient>
<name>
<surname>Tavera</surname>
<given-names>Gloria R.</given-names>
</name>
<name>
<surname>Jose</surname>
<given-names>Pedro A.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution>National Institute of Health </institution>
</funding-source>
<award-id>HL092196</award-id>
<award-id>R01LM010098</award-id>
<principal-award-recipient>
<name>
<surname>Williams</surname>
<given-names>Scott M.</given-names>
</name>
<name>
<surname>Jose</surname>
<given-names>Pedro A.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution>Philippine Genome Center</institution>
</funding-source>
<award-id>None</award-id>
<principal-award-recipient>
<name>
<surname>Palmes-Saloma</surname>
<given-names>Cynthia P.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution>Gilliam Fellowship from the Howard Hughes Medical Institute </institution>
</funding-source>
<award-id>None</award-id>
<principal-award-recipient>
<name>
<surname>Tavera</surname>
<given-names>Gloria R.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000912</institution-id>
<institution>March of Dimes Foundation</institution>
</institution-wrap>
</funding-source>
<award-id>none</award-id>
<principal-award-recipient>
<name>
<surname>Williams</surname>
<given-names>Scott M.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par28">Hypertensive disorders of pregnancy account for 36.7% of all maternal deaths in the Philippines [<xref ref-type="bibr" rid="CR1">1</xref>], which is much higher than the worldwide rate of 18% [<xref ref-type="bibr" rid="CR2">2</xref>]. Included among these hypertensive diseases affecting pregnant women is preeclampsia, a severe and diverse disorder that is associated with life-threatening multi-organ maternal complications and which causes serious feto-placental problems. It accounted for 22.5% of hypertensive patient admissions at the hospital where this study was conducted [<xref ref-type="bibr" rid="CR3">3</xref>].</p>
<p id="Par29">Preeclampsia is a multifactorial disease, with both genetic and environmental factors contributing to its development. Multiple interrelated pathways have been suggested to contribute to its pathogenesis. Previous studies have tested genes with potential biological relevance in specific pathways to ascertain whether certain variants influence the disease process. The biological pathways impacted by preeclampsia include but are not limited to aberrant placental development and dysfunctional hemodynamic and renal functions, impaired immune function, free radical dysregulation and lipid peroxidation, and defects in coagulation and fibrinolysis. We have previously found variants of the <italic>VEGF-A</italic> and <italic>VEGFR1</italic> genes to associate with preeclampsia among Filipinos, an ethnically distinct group with high prevalence [<xref ref-type="bibr" rid="CR4">4</xref>]. These genes are important in angiogenesis, a critical process in the establishment of normal pregnancy and in preeclampsia.</p>
<p id="Par30">The effect of single gene variation will likely be contingent on other genetic variations (gene-gene interaction, or epistasis) and environmental factors (gene-environment interaction). Since many genes and environmental factors interact to cause multifactor and polygenic diseases, including preeclampsia, the effect of any single gene may be too small to be detected using traditional statistical methods, which do not take these interactions into account<bold>.</bold> The multifactor dimensionality reduction (MDR) algorithm has been designed as an alternative to traditional statistical methods to deal with high-order gene/factor interactions [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. MDR has many other advantages over traditional methods. It is model-free, i.e., it does not assume any particular genetic model, and requires only a small sample size that can be used for case-control studies [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR7">7</xref>]<bold>.</bold> MDR has been successfully applied in detecting gene-gene interactions for a number of clinical phenotypes, which include bronchial asthma [<xref ref-type="bibr" rid="CR8">8</xref>], autism [<xref ref-type="bibr" rid="CR9">9</xref>], essential hypertension [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], and type II diabetes [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
<p id="Par31">In this study, we evaluated the role of contextual effects in the development of preeclampsia among Filipino women by analyzing 29 previously reported susceptibility SNPs found in 21 genes. The 21 genes are involved in various pathways that regulate the processes implicated in the development of preeclampsia and are as follows: endothelial/angiogenesis (<italic>VEGFA, VEGFC, VEGFR1, VEGFR3</italic>); dopaminergic system (<italic>GRK4, DRD1</italic>); renin-angiotensin system (<italic>AGT</italic>); immunity and inflammation (<italic>ERAP2, CTLA4, IL1A, TNSF13B</italic>); lipid metabolism (<italic>LPL</italic>); oxidative stress and detoxification (<italic>eNOS, CYP1A2, PON1, EPHX1, GSTP1);</italic> key signaling proteins (<italic>ACVR2A</italic>), hormone and neurotransmitter regulation (<italic>COMT</italic>) and protein biosynthesis (<italic>MTR</italic> and <italic>MTRR</italic>).</p>
</sec>
<sec id="Sec2">
<title>Methods</title>
<p id="Par32">This is a case-control study that included 381 individuals. Of these, 56 were removed in the final analysis because they had more than 2 genotypes missing. Of the 325 that remained, 150 were patients with preeclampsia (cases) and 175 were women with uncomplicated normal pregnancies (controls). Subjects were recruited upon admission to the hospital and were followed up until 6 weeks after delivery. Subjects included in the normal pregnancy control group had blood pressures ≤120/80 mmHg, consistent with the latest guidelines on hypertension [<xref ref-type="bibr" rid="CR13">13</xref>]. Blood pressure was measured according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [<xref ref-type="bibr" rid="CR14">14</xref>] and verified twice with at least a 4-h interval. Exclusion criteria for the control group were a history of hypertension and pregnancy-induced hypertension, multiple pregnancy, molar pregnancy, personal and family history of diabetes mellitus, ischemic heart disease, cerebrovascular accident, and renal disease.</p>
<p id="Par33">Included in the preeclampsia group were patients who had a resting systolic blood pressure ≥ 140 mmHg and/or a diastolic blood pressure ≥ 90 mmHg and had proteinuria after 20 weeks of gestation. Proteinuria was defined as ≥300 mg protein in a 24-h urine collection or a urine protein dipstick of ≥2+. Exclusion criteria for the preeclampsia group were a history of hypertension, renal disease, proteinuria before the 20th week of pregnancy, multiple pregnancy, diabetes mellitus, ischemic heart disease, cerebrovascular accident, and renal disease.</p>
<p id="Par34">This study was undertaken in accordance with the Declaration of Helsinki at the Department of Obstetrics and Gynecology of the University of the Philippines, Philippine General Hospital (UP-PGH) in Manila. All subjects provided informed written consent. The study was approved by the UP-PGH Ethics Review Board.</p>
<sec id="Sec3">
<title>SNP selection, blood sampling, DNA extraction, and genotyping</title>
<p id="Par35">The candidate genes and respective variants were selected from different pathophysiological pathways involved in the development of preeclampsia and based on previous association studies. The <italic>ACVR2A</italic> SNPs in particular have been shown to be associated with preeclampsia in a study involving Brazilian [<xref ref-type="bibr" rid="CR15">15</xref>] and Norwegian women [<xref ref-type="bibr" rid="CR16">16</xref>]. Criteria for SNP selection included SNPs for which an association with preeclampsia has been reported in other ethnic populations and those that are also supported by the platform used for genotyping. The gene variants in relevant pathways include: endothelial/angiogenesis (<italic>VEGFA</italic> [<xref ref-type="bibr" rid="CR17">17</xref>–<xref ref-type="bibr" rid="CR19">19</xref>], <italic>VEGFC</italic> [<xref ref-type="bibr" rid="CR20">20</xref>], <italic>VEGFR1</italic> [<xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR22">22</xref>]; renin-angiotensin system (<italic>AGT</italic> [<xref ref-type="bibr" rid="CR23">23</xref>–<xref ref-type="bibr" rid="CR25">25</xref>]); immunity and inflammation (<italic>ERAP2</italic> [<xref ref-type="bibr" rid="CR26">26</xref>], <italic>CTLA4</italic> [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], <italic>IL1A</italic> [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>], <italic>TNSF13B</italic> [<xref ref-type="bibr" rid="CR31">31</xref>]); lipid metabolism (<italic>LPL</italic> [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]); oxidative stress and detoxification (<italic>eNOS</italic> [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>], <italic>CYP1A2</italic> [<xref ref-type="bibr" rid="CR35">35</xref>], <italic>PON1</italic> [<xref ref-type="bibr" rid="CR36">36</xref>–<xref ref-type="bibr" rid="CR39">39</xref>], <italic>EPHX1</italic> [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>], <italic>GSTP1</italic> [<xref ref-type="bibr" rid="CR42">42</xref>])<italic>;</italic> key signaling proteins (<italic>ACVR2A</italic> [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]), hormone and neurotransmitter regulation (<italic>COMT</italic> [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]) and protein biosynthesis (<italic>MTR</italic> and <italic>MTRR</italic>) [<xref ref-type="bibr" rid="CR45">45</xref>–<xref ref-type="bibr" rid="CR48">48</xref>]. Also included are SNPs in the dopaminergic system (<italic>GRK4</italic> [<xref ref-type="bibr" rid="CR49">49</xref>–<xref ref-type="bibr" rid="CR52">52</xref>] and <italic>DRD1</italic> [<xref ref-type="bibr" rid="CR52">52</xref>]), which have been established to be associated strongly with hypertension.</p>
<p id="Par36">Venous blood samples for DNA extraction and genotyping were collected after a definitive diagnosis of preeclampsia or normal pregnancy. Three milliliters of venous blood were extracted at the time of hospital admission by venipuncture at the antecubital fossa, collected in a vacutainer with EDTA, and stored at 4 °C until DNA extraction. DNA was extracted from the peripheral blood mononuclear cells using the QIAamp® DNA Mini Kit. DNA purity and quantity were determined using a Nanodrop 2000 spectrometer (Thermo Scientific, Waltham, MA, USA). The DNA was stored at 4 °C until genetic profiling. Genotyping of the <italic>GRK4</italic> and <italic>DRD1</italic> variants was carried out using the TaqMan Assay at the University of Maryland Biopolymer-Genomics Core Facility. Genotyping of the other genes was carried out using the Sequenom MassARRAY Iplex Platform at the Center for Genomic Sciences of the University of Hong Kong. Repeat genotyping for 16 samples was performed for quality control.</p>
</sec>
<sec id="Sec4">
<title>Statistical analysis</title>
<p id="Par37">Statistical analysis for the clinical parameters was performed using STATA software, version 14.1 [<xref ref-type="bibr" rid="CR53">53</xref>]. All values were expressed as mean/median ± standard error, while the association of known categorical risk factors was analyzed using Pearson’s chi-square test. Odds ratios (OR) were calculated to determine the odds of developing preeclampsia when the individual had the clinical factor of interest. OR was used for binary logistic regression and multinomial logistic regression. Minor allele frequencies and Hardy-Weinberg Equilibrium were calculated for each SNP using PLINK 1.9. Of the 29 SNPs, 6 were removed from further analysis (<italic>AGT</italic>, <italic>LPL</italic>, <italic>FLT1, ERAP1, FLT4 and TNFSF13B</italic>) because these SNPs were monomorphic, or had a minor allele frequency below 5%. Accumulated/average Cross Validation testing, training, consistency and permutation <italic>P</italic> values were calculated using MDR [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. The MDR algorithm and ViSEN software [<xref ref-type="bibr" rid="CR55">55</xref>] were applied to the genetic data to enable the detection and characterization of epistatic SNP-SNP interactions and SNP-clinical factor (age and BMI) interaction. To identify a correct multi-locus model, the Acc. CV testing (Accumulated/average Cross Validation testing) and CV Consistency (Cross Validation Consistency) were calculated for each model.</p>
</sec>
</sec>
<sec id="Sec5">
<title>Results</title>
<p id="Par38">Normal pregnancies and preeclampsia outcomes differed in several demographic and clinical characteristics. Mothers with normal pregnancies were significantly younger (25.2 vs. 30.3; <italic>P</italic> = &lt; 1 × 10<sup>− 4</sup>) (Table <xref ref-type="table" rid="Tab1">1</xref>) and had lower BMI (21.75 vs. 23.5; <italic>P</italic> = &lt; 1 × 10<sup>− 4</sup>) (Table <xref ref-type="table" rid="Tab1">1</xref>). The mean interval from last pregnancy was shorter in normal outcomes (2.03 years vs. 2.87 years; <italic>P</italic> = 0.018). Having a new partner also associated with preeclampsia (<italic>P</italic> = 0.006). However, neither smoking (<italic>P</italic> = 0.957) nor gravidity (<italic>P</italic> = 0.435) associated with preeclampsia (Table <xref ref-type="table" rid="Tab2">2</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Age, BMI, and interval year are risk factors for preeclampsia</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Category</th><th>Mean/Median</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td rowspan="2">Age</td><td>NP</td><td>Mean: 25.2 ± 0.45 Median: 24</td><td></td></tr><tr><td>PE</td><td>Mean: 30.3 ± 0.53 Median: 31</td><td>&lt;  1 × 10<sup>−4</sup>*</td></tr><tr><td rowspan="2">BMI<sup>3</sup></td><td>NP</td><td>Mean: 21.75 ± 0.19 Median: 21.39</td><td></td></tr><tr><td>PE</td><td>Mean: 23.5 ± 0.21 Median: 23.31</td><td>&lt;  1 × 10<sup>−4</sup>*</td></tr><tr><td rowspan="2">Interval Year</td><td>NP</td><td>Mean: 2.03 ± 0.21 Median: 1</td><td></td></tr><tr><td>PE</td><td>Mean: 2.87 ± 0.28 Median: 1</td><td>0.018*</td></tr></tbody></table><table-wrap-foot><p>Data are expressed as mean ± SEM and median; odds ratio (OR) used for binary logistic regression</p><p><italic>NP</italic> Normal pregnancy, <italic>PE</italic> Preeclampsia, <italic>BMI</italic> Body mass index</p><p>*<italic>P</italic> values &lt; 0.05 are statistically significant</p><p>The table summarizes the demographic, clinical characteristics, and risk factors of preeclampsia patients and controls with normal pregnancy. The preeclampsia patients were generally older, had higher BMI, and longer interval year from previous pregnancy compared with control subjects.</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>A new partner is a risk factor for preeclampsia</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Category</th><th>No</th><th>Yes</th><th>Pearson’s correlation</th><th><italic>P</italic> value</th><th>OR</th></tr></thead><tbody><tr><td rowspan="2">Smoking</td><td>NP</td><td>181</td><td>17</td><td></td><td></td><td></td></tr><tr><td>PE</td><td>167</td><td>16</td><td align="char" char=".">0.003</td><td align="char" char=".">0.957</td><td align="char" char=".">1.020077</td></tr><tr><td rowspan="2">Alcohol</td><td>NP</td><td>184</td><td>14</td><td></td><td></td><td></td></tr><tr><td>PE</td><td>165</td><td>18</td><td align="char" char=".">1.737</td><td align="char" char=".">0.333</td><td align="char" char=".">1.433766</td></tr><tr><td rowspan="2">Nulliparous</td><td>NP</td><td>109</td><td>89</td><td></td><td></td><td></td></tr><tr><td>PE</td><td>108</td><td>75</td><td align="char" char=".">0.61</td><td align="char" char=".">0.435</td><td align="char" char=".">0.8504994</td></tr><tr><td></td><td></td><td>Previous</td><td>New</td><td></td><td></td><td></td></tr><tr><td rowspan="2">Partner</td><td>NP</td><td>173</td><td>25</td><td></td><td></td><td></td></tr><tr><td>PE<sup>2</sup></td><td>140</td><td>43</td><td align="char" char=".">7.67</td><td align="char" char=".">0.006*</td><td align="char" char=".">2.125</td></tr></tbody></table><table-wrap-foot><p>Data used odds ratio (OR) for binary logistic regression and for multinomial logistic regression</p><p><italic>NP</italic> Normal pregnancy, <italic>PE</italic> Preeclampsia</p><p>*<italic>P</italic> values &lt; 0.05 are statistically significant</p><p>Among the risk factors analyzed (smoking, alcoholic beverage consumption, nulliparity, and having a new partner) in preeclampsia patients and controls with normal pregnancy, only having a new partner was associated with increased risk of preeclampsia.</p></table-wrap-foot></table-wrap></p>
<p id="Par41">No SNPs associated with preeclampsia in the unadjusted analyses (Table <xref ref-type="table" rid="Tab3">3</xref>). Association of single SNPs was also run adjusting for age, BMI, interval between pregnancies, and new partner (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S1). After adjusting for these covariates, one SNP reached nominal statistical significance (<italic>VEGF-A</italic> rs3025039; <italic>P</italic> = 0.022). This was not significant after adjusting for multiple testing (Bonferroni threshold <italic>P</italic> = 0.0023).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Gene variants included in the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Chr</th><th>SNP</th><th>Gene</th><th>Product (processes involved in)</th><th>MAF</th><th>OR</th><th>Allelic<break></break><italic>P</italic> value</th><th>Genotypic<break></break><italic>P</italic> value</th></tr></thead><tbody><tr><td>1</td><td>rs1051740</td><td>
<italic>EPHX1</italic>
</td><td>Epoxide hydrolase (xenobiotic metabolism)</td><td>0.4547</td><td>1.039</td><td>0.8109</td><td>0.6148</td></tr><tr><td>1</td><td>rs699</td><td>
<italic>AGT</italic>
</td><td>Angiotensinogen (products elicit vasoconstriction)</td><td>0.1277</td><td>1.098</td><td>0.6899</td><td>NA</td></tr><tr><td>1</td><td>rs1805087</td><td>
<italic>MTR</italic>
</td><td>5-Methyltetrahydrofolate-Homocysteine Methyltransferase (methionine biosynthesis)</td><td>0.1357</td><td>1.013</td><td>0.9568</td><td>NA</td></tr><tr><td>2</td><td>rs3783550</td><td>
<italic>IL1A</italic>
</td><td>Interleukin 1-alpha (immunity, inflammation, hematopoiesis)</td><td>0.2031</td><td>1.003</td><td>0.988</td><td>0.7627</td></tr><tr><td>2</td><td>rs1014064</td><td>
<italic>ACVR2A</italic>
</td><td rowspan="2">Activin A Receptor Type 2A (growth and differentiation)</td><td>0.4414</td><td>0.8699</td><td>0.3805</td><td>0.556</td></tr><tr><td>2</td><td>rs2161983</td><td>
<italic>ACVR2A</italic>
</td><td>0.4385</td><td>0.8921</td><td>0.4717</td><td>0.5188</td></tr><tr><td>2</td><td>rs231775</td><td>
<italic>CTLA-4</italic>
</td><td>Cytotoxic T-Lymphocyte Associated Protein 4 (inhibition of immune responses)</td><td>0.4462</td><td>1.22</td><td>0.216</td><td>0.4626</td></tr><tr><td>4</td><td>rs2960306</td><td>
<italic>GRK4</italic>
</td><td rowspan="3">G protein-coupled receptor kinase 4 (receptor desensitization)</td><td>0.0679</td><td>1.763</td><td>0.0709</td><td>NA</td></tr><tr><td>4</td><td>rs1024323</td><td>
<italic>GRK4</italic>
</td><td>0.1354</td><td>1.26</td><td>0.3133</td><td>NA</td></tr><tr><td>4</td><td>rs1801058</td><td>
<italic>GRK4</italic>
</td><td>0.4599</td><td>1.024</td><td>0.8797</td><td>0.8192</td></tr><tr><td>4</td><td>rs7664413</td><td>
<italic>VEGF-C</italic>
</td><td>Vascular endothelial growth factor C (lymphangiogenesis)</td><td>0.2436</td><td>1.316</td><td>0.1412</td><td>0.181</td></tr><tr><td>5</td><td>rs1801394</td><td>
<italic>MTRR</italic>
</td><td>Methionine synthase reductase (methionine biosynthesis)</td><td>0.2754</td><td>0.9219</td><td>0.645</td><td>0.8572</td></tr><tr><td>5</td><td>rs2549782</td><td>
<italic>ERAP 2</italic>
</td><td>Endoplasmic reticulum aminopeptidase 2 (antigen processing)</td><td>0.4046</td><td>1.097</td><td>0.5622</td><td>0.8404</td></tr><tr><td>5</td><td>rs4532</td><td>
<italic>DRD1</italic>
</td><td>Dopamine D1 receptor (sodium transport, blood pressure regulation)</td><td>0.2105</td><td>1.01</td><td>0.9594</td><td>0.9148</td></tr><tr><td>6</td><td>rs2010963</td><td>
<italic>VEGF-A</italic>
</td><td rowspan="2">Vascular endothelial growth factor A (angiogenesis, vasculogenesis, endothelial cell growth &amp; migration)</td><td>0.223</td><td>0.8585</td><td>0.4495</td><td>NA</td></tr><tr><td>6</td><td>rs3025039</td><td>
<italic>VEGF-A</italic>
</td><td>0.1188</td><td>0.6282</td><td>0.0626</td><td>NA</td></tr><tr><td>7</td><td>rs662</td><td>
<italic>PON1</italic>
</td><td>Paraoxonase 1 (inactivation of organophosphates, inhibition of atherosclerosis formation)</td><td>0.4306</td><td>0.9923</td><td>0.9612</td><td>0.9841</td></tr><tr><td>7</td><td>rs1799983</td><td>
<italic>NOS3</italic>
</td><td>Endothelial NOS (vascular relaxation, antioxidant activity)</td><td>0.1813</td><td>0.9324</td><td>0.7342</td><td>0.829</td></tr><tr><td>11</td><td>rs1695</td><td>
<italic>GSTP1</italic>
</td><td>Glutathione S-Transferase Pi 1 (xenobiotic metabolism)</td><td>0.2954</td><td>1.073</td><td>0.6809</td><td>0.8688</td></tr><tr><td>13</td><td>rs12584067</td><td>
<italic>VEGFR-1</italic>
</td><td>Vascular endothelial growth factor receptor 1 (cell proliferation and differentiation</td><td>0.0776</td><td>1.282</td><td>0.3978</td><td>NA</td></tr><tr><td>13</td><td>rs722503</td><td>
<italic>VEGFR-1</italic>
</td><td>Vascular endothelial growth factor receptor 1 (cell proliferation and differentiation</td><td>0.1660</td><td>0.8019</td><td>0.3593</td><td>NA</td></tr><tr><td>15</td><td>rs2470890</td><td>
<italic>CYP1A2</italic>
</td><td>Cytochrome P450 1A2 (xenobiotic metabolism)</td><td>0.0923</td><td>0.8182</td><td>0.4643</td><td>NA</td></tr><tr><td>22</td><td>rs4633</td><td>
<italic>COMT</italic>
</td><td>Catechol-O-methyltransferase (degrades catecholamines)</td><td>0.1692</td><td>1.056</td><td>0.7962</td><td>NA</td></tr></tbody></table><table-wrap-foot><p><italic>Chr</italic> Chromosome, <italic>SNP</italic> Single nucleotide polymorphism, <italic>MAF</italic> Minor allele frequencies, <italic>OR</italic> Odds ratio, <italic>NA</italic> Not appplicable</p><p>The alleles and genotypes of the SNPs are not associated with preeclampsia when analyzed using PLINK<bold>.</bold> NA corresponds to the inability to determine a genotypic P value, due to a small number of counts in at least 1 of the 3 genotypes (i.e., AA/AT/TT not present, only AA/AT), thus, only allelic <italic>P</italic> value is given.</p></table-wrap-foot></table-wrap></p>
<p id="Par43">Context-dependent effects were assessed using MDR. Only one model that included a genetic variant, as well as the significant demographic and clinical variables, was statistically significant; it included maternal age as three categories (18–25; 26–35; 36-Older); maternal BMI as three categories (13–17.97; 18–25; 25.1-Above) and rs1014064 (cross validation testing prediction = 60.95%; permutation <italic>P</italic> = 0.005 and cross validation consistency = 7/10) (Table <xref ref-type="table" rid="Tab4">4</xref>). Upon examining the model, it was evident that the genetic effect was present primarily in the middle range of BMI (18–25) (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). In low BMI ranges (13–17.97), the outcome was dominated by a protective effect and in high BMI ranges (25.1-above) by a risk-increasing effect of body mass. When re-analyzing only the middle range of BMI (18–25), genetics appeared to play a significant non-additive role (cross validation testing prediction = 64.88%; permutation <italic>p</italic> = &lt; 1 × 10<sup>− 4</sup> and cross validation consistency = 10/10; Fig. <xref ref-type="fig" rid="Fig1">1</xref>). There was no statistical epistasis detected using ViSEN.<table-wrap id="Tab4"><label>Table 4</label><caption><p>MDR analysis of genetic variants, adjusting for age and BMI</p></caption><table frame="hsides" rules="groups"><thead><tr><th>SNP rs1014064</th><th>GENE <italic>ACVR2A</italic></th><th colspan="2"></th></tr><tr><th>INTERACTION</th><th>Acc. CV Testing</th><th>CV Consistency</th><th></th></tr></thead><tbody><tr><td>Age</td><td>0.6457</td><td>10/10</td><td></td></tr><tr><td>Age, BMI</td><td>06729</td><td>10/10</td><td></td></tr><tr><td>rs1014064, Age, BMI</td><td>0.6095</td><td>7/10</td><td><italic>P</italic> = 0.005*</td></tr></tbody></table><table-wrap-foot><p>There is an interaction between <italic>ACVR2A</italic> rs1014064, age, and BMI</p><p><italic>MDR</italic> Multifactor dimensionality reduction, <italic>SNP</italic> Single nucleotide polymorphism, <italic>BMI</italic> Body mass index</p><p>*<italic>P</italic> value &lt; 0.05 is statistically significant</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>MDR model for interaction of rs1014064, age, and BMI. Each cell shows counts of preeclampsia on the left and normal pregnancy on the right. When re-analyzing only the middle range of BMI (18–25), genetics appeared to play a significant non-additive role in predicting preeclampsia, <italic>P</italic> &lt; 1 × 10<sup>− 4</sup>, cross validation testing prediction = 64.88%, cross validation consistency = 10/10; MDR, multifactor dimensionality reduction; BMI, body mass index</p></caption><graphic id="MO1" xlink:href="12884_2018_2152_Fig1_HTML"></graphic></fig></p>
<p id="Par44">The genetic data were analyzed for epistasis using MDR and ViSEN statistical software. Table <xref ref-type="table" rid="Tab3">3</xref> summarizes the different gene variants that were included in the analysis, as well as pertinent information for each, including the gene product and the processes in which it is involved, chromosome location, minor allele frequencies (MAF), and odds ratio (OR). Monomorphic SNPs (<italic>VEGFR1</italic> rs7335588, <italic>AGT</italic> rs41271499, and <italic>LPL</italic> rs268) and with MAF &lt; 0.05 (<italic>VEGFR3</italic> rs307826, <italic>ERAP2</italic> rs17408150, and <italic>TNFSF13B</italic> rs16972194) were excluded from analyses. Genotype frequencies for all the SNPs were in Hardy-Weinberg equilibrium.</p>
</sec>
<sec id="Sec6">
<title>Discussion</title>
<p id="Par45">Non-linear interactions among multiple genetic and environmental or clinical factors are now understood to be important components in understanding the underlying pathogenesis, especially when considering the genetic bases of complex diseases such as preeclampsia. The MDR algorithm is a well-known data mining strategy that provides an improved representation of the genotypic and phenotypic data and enables better detection of higher-order interactions, such as epistatic interactions [<xref ref-type="bibr" rid="CR6">6</xref>]. In the current study, MDR identified a four-locus model that underscores a possible interaction among rs1014064 (<italic>ACVR2A</italic>), rs7664413 (<italic>VEGF-C</italic>), rs2549782 (<italic>ERAP2</italic>), and rs662 (<italic>PON1</italic>) variants when un-adjusted for age or BMI (Additional file <xref ref-type="media" rid="MOESM2">2</xref>: Table S2). However, when age and BMI were adjusted for, these effects disappeared. A significant interaction was found in a model involving the genetic variant rs1014064 (<italic>ACVR2A</italic>) and the demographic and clinical variables, age and BMI.</p>
<p id="Par46">The significant gene identified, <italic>ACVR2A</italic>, encodes the receptor for Activin A. ACVR2A expression in the placenta throughout pregnancy indicates its possible role in the regulation of placental development and function [<xref ref-type="bibr" rid="CR56">56</xref>]. Initial studies have shown a linkage between preeclampsia and various parts of chromosome 2, where the <italic>ACVR2A</italic> gene is localized. The first reported locus for preeclampsia that met the criteria for genome-wide association significance was seen in chromosome 2p13 and 2q23 in a study involving Icelandic families, representing 343 affected women [<xref ref-type="bibr" rid="CR57">57</xref>]. Two other genome-wide association studies identified other loci in chromosome 2 distinct from those seen in the initial study, i.e., 2p25 in 15 families with 49 affected women from Finland [<xref ref-type="bibr" rid="CR58">58</xref>] and 2p11–12 and 2q22 involving 34 families, representing 121 affected women from Australia and New Zealand [<xref ref-type="bibr" rid="CR59">59</xref>]. With the reported significant linkage to chromosome 2q22, the same group identified the <italic>ACVR2A</italic> gene as a strong positional candidate gene [<xref ref-type="bibr" rid="CR60">60</xref>].</p>
<p id="Par47">The MDR analysis identified the <italic>ACVR2A</italic> rs1014064, an intronic variant (A to G), as the only significant variant. This variant associated with preeclampsia in a large Norwegian population-based study (the HUNT study), together with the other <italic>ACVR2A</italic> variant (rs2161983) [<xref ref-type="bibr" rid="CR16">16</xref>], which was also evaluated and found not associated with preeclampsia in this study, and with early onset preeclampsia in a Brazilian population [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
<p id="Par48">MDR has been used to identify the important role of epistasis in polygenic disorders, such as sporadic breast cancer [<xref ref-type="bibr" rid="CR6">6</xref>] and essential hypertension. A two-locus model including <italic>ACE</italic> and <italic>GRK4</italic> successfully predicted the blood pressure phenotype 70.5% of the time [<xref ref-type="bibr" rid="CR10">10</xref>]<bold>.</bold> A genetic model based on the three common <italic>GRK4</italic> SNPs was 94.4% predictive of salt-sensitive hypertension, while a single-locus model with only the <italic>GRK4</italic> A142V variant was 78.4% predictive. By contrast, for low-renin hypertension, a two-locus model that includes the <italic>GRK4</italic> A142V variant and cytochrome P450 11B2 (<italic>CYP11B2</italic>) C-344 T was 77.8% predictive [<xref ref-type="bibr" rid="CR11">11</xref>]. These results reflect the differences in the underlying genetics and the crucial role of epistasis in the development of the different hypertension-related phenotypes. Considering the spectrum of the clinical presentation of preeclampsia, it is conceivable that different phenotypes of the disease may involve specific gene polymorphisms, i.e., locus heterogeniety. In fact, the presence of severe forms of preeclampsia, HELLP syndrome and eclampsia, have been suggested to have their own set of predisposing gene variants. It is therefore important to know which specific genes contribute the most to their development.</p>
<p id="Par49">We also used ViSEN software, which provides a global interaction map to identify and corroborate risk-associated SNPs, visualize putative gene interactions and generate an interaction or concept map for preeclampsia. Similar to what we observed using MDR, we detected no statistically significant two- and three-way epistatic interactions with ViSEN. Due to its limitation to analyze only up to three-way epistasis, the four-locus model that we observed with MDR was undetected. Moreover, ViSEN as a statistical tool has its own limitations, e.g., the statistical epistasis quantifications in ViSEN only consider discrete traits and cannot incorporate measures on continuous traits like age and BMI [<xref ref-type="bibr" rid="CR55">55</xref>].</p>
<p id="Par50">In the analysis of genetic datasets, an important consideration is the power of analytical methods to identify accurate predictive models of disease. The MDR approach overcomes the common setbacks found in other methods. It is non-parametric, model-free, and can identify high-order gene-gene interactions [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. It retains its power to analyze in the presence of genotyping error and missing data (up to 5%). However, it has its own limitations, including a decrease in power in the presence of phenocopies and genetic heterogeneity [<xref ref-type="bibr" rid="CR61">61</xref>].</p>
<p id="Par51">With respect to marginal effects, one of the SNPs we genotyped in VEGF-A, rs3025039, that was previously identified as associating with preeclampsia in the Philippines [<xref ref-type="bibr" rid="CR4">4</xref>] also showed a marginal association in our data set when adjusting for covariates (<italic>p</italic> = 0.022). Although this result would not stand after adjusting for multiple testing, as a replication it provided additional evidence that this variant confers pre-eclampsia risk especially since the direction of effect was the same in the present and the previous studies. A second SNP in this gene, rs722503, that was previously reported to be associated with preeclampsia, but only in pregnancies with women over 40, did not show evidence for significance in the current study (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S1). Of note, in the age and BMI adjusted model for rs722503 the <italic>p</italic> value did get smaller as compared to the unadjusted model, which is consistent with an age-related effect. This, however, was not surprising as very few pregnancies involved women over 40 (4). In addition, this SNP did not appear in our MDR analyses when all other SNPs were included.</p>
<p id="Par52">A notable limitation of this study is the non-inclusion of other SNPs that have been shown to be associated with preeclampsia in specific ethnic groups, or more importantly in multi-gene meta-analysis studies involving different ethnic groups [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>] and in multigene association studies [<xref ref-type="bibr" rid="CR64">64</xref>]. These include the gene variants <italic>of FV, F2, ACE, SERPINE1, AGTR1, MTHFR,</italic> and <italic>MMP-9</italic>. The <italic>ACE</italic> gene variant is an insertion/deletion polymorphism, which cannot be detected by the method used for genotyping in our studies. The other genes, although included in the initial list for analysis, were eventually dropped from the analysis due to technical problems. These genes, however, should be included in future studies.</p>
</sec>
<sec id="Sec7">
<title>Conclusions</title>
<p id="Par53">Preeclampsia is a multifactorial disease, with both genetic and environmental factors contributing to its development. Genetic variants from multiple, interrelated pathways have been suggested to contribute to the pathogenesis of the disease. The MDR algorithm enabled the analysis of high-order gene/factor interactions and identified <italic>ACVR2A</italic> rs1014064 as important in modulating preeclampsia risk among older Filipino women with a middle-range BMI.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Additional files</title>
<sec id="Sec8">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12884_2018_2152_MOESM1_ESM.docx"><label>Additional file 1:</label><caption><p><bold>Table S1.</bold> Association of SNPs, adjusting for statistically significant risk factors. (DOCX 16 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12884_2018_2152_MOESM2_ESM.docx"><label>Additional file 2:</label><caption><p><bold>Table S2.</bold> MDR analysis of genetic variants, without adjusting for age and BMI. (DOCX 14 kb)</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>
<italic>ACVR2A</italic>
</term>
<def>
<p id="Par5">Activin A Receptor Type 2A</p>
</def>
</def-item>
<def-item>
<term>
<italic>AGT</italic>
</term>
<def>
<p id="Par6">Angiotensinogen</p>
</def>
</def-item>
<def-item>
<term>
<italic>COMT</italic>
</term>
<def>
<p id="Par7">Catechol-O-methyltransferase</p>
</def>
</def-item>
<def-item>
<term>
<italic>CTLA4</italic>
</term>
<def>
<p id="Par8">Cytotoxic T-Lymphocyte Associated Protein 4</p>
</def>
</def-item>
<def-item>
<term>
<italic>CYP1A2</italic>
</term>
<def>
<p id="Par9">Cytochrome P450 family 1 subfamily A member 2</p>
</def>
</def-item>
<def-item>
<term>
<italic>DRD1</italic>
</term>
<def>
<p id="Par10">Dopamine D1 receptor</p>
</def>
</def-item>
<def-item>
<term>
<italic>eNOS</italic>
</term>
<def>
<p id="Par11">Endothelial nitric oxide synthase</p>
</def>
</def-item>
<def-item>
<term>
<italic>EPHX1</italic>
</term>
<def>
<p id="Par12">Epoxide hydrolase</p>
</def>
</def-item>
<def-item>
<term>
<italic>ERAP2</italic>
</term>
<def>
<p id="Par13">Endoplasmic reticulum aminopeptidase 2</p>
</def>
</def-item>
<def-item>
<term>
<italic>GRK4</italic>
</term>
<def>
<p id="Par14">G protein-coupled receptor kinase 4</p>
</def>
</def-item>
<def-item>
<term>
<italic>GSTP1</italic>
</term>
<def>
<p id="Par15">Glutathione S-Transferase Pi 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>IL1A</italic>
</term>
<def>
<p id="Par16">Interleukin 1-alpha</p>
</def>
</def-item>
<def-item>
<term>
<italic>LPL</italic>
</term>
<def>
<p id="Par17">
<italic>Lipoprotein lipase</italic>
</p>
</def>
</def-item>
<def-item>
<term>MDR</term>
<def>
<p id="Par18">Multifactor dimensionality reduction</p>
</def>
</def-item>
<def-item>
<term>
<italic>MTR</italic>
</term>
<def>
<p id="Par19">5-Methyltetrahydrofolate-Homocysteine Methyltransferase</p>
</def>
</def-item>
<def-item>
<term>
<italic>MTRR</italic>
</term>
<def>
<p id="Par20">Methionine synthase reductase</p>
</def>
</def-item>
<def-item>
<term>
<italic>PON1</italic>
</term>
<def>
<p id="Par21">Paraoxonase 1</p>
</def>
</def-item>
<def-item>
<term>SNPs</term>
<def>
<p id="Par22">Single nucleotide polymorphisms</p>
</def>
</def-item>
<def-item>
<term>
<italic>TNSF13B</italic>
</term>
<def>
<p id="Par23">Tumor necrosis factor ligand superfamily member 13B</p>
</def>
</def-item>
<def-item>
<term>
<italic>VEGFA</italic>
</term>
<def>
<p id="Par24">Vascular endothelial growth factor A</p>
</def>
</def-item>
<def-item>
<term>
<italic>VEGFC</italic>
</term>
<def>
<p id="Par25">Vascular endothelial growth factor C</p>
</def>
</def-item>
<def-item>
<term>
<italic>VEGFR1</italic>
</term>
<def>
<p id="Par26">Vascular endothelial growth factor receptor 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>VEGFR3</italic>
</term>
<def>
<p id="Par27">Vascular endothelial growth factor receptor 3</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Acknowledgements</title>
<p>Not Applicable.</p>
<sec id="FPar1">
<title>Funding</title>
<p id="Par54">This study was supported by a grant from University of the Philippines Emerging Interdisciplinary Research (EIDR) Program and the Philippine Genome Center; and in part by the authors’ respective grants: NIH CTSA grant TL1 TR000441 and the Gilliam Fellowship from the Howard Hughes Medical Institute (GRT); a minigrant from the National Kidney Foundation of Maryland (VMV); NIH grants R37HL023081, HL092196 (PAJ): NIH grant R01LM010098 and a grant from March of Dimes (SMW). Funding bodies had no role in the design of the study and collection, analysis, interpretation of data, and in writing the manuscript.</p>
</sec>
<sec id="FPar2">
<title>Availability of data and materials</title>
<p id="Par55">The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.</p>
</sec>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>MDA, VMV PAJ, CPS conceived and designed the study; MDA, JAN performed the experiments; LDB clinical input; JAN contributed in the initial analysis, interpretation of results, and manuscript preparation; GRT, SMW analyzed the data; MDA, GRT wrote the final paper; VMV, CPS, PAJ, SMW, review and editing; CPS, PAJ, SMW, VMV, funding acquisition. All authors read and approved the final draft of the manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<sec id="FPar3">
<title>Ethics approval and consent to participate</title>
<p>This study was approved by the University of the Philippines, Philippine General Hospital (UP-PGH) Ethics Review Board. All subjects provided informed written consent.</p>
</sec>
<sec id="FPar4">
<title>Consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec id="FPar5">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<sec id="FPar6">
<title>Publisher’s Note</title>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<mixed-citation publication-type="other">Department of Health - National Epidemiology Center. The 2013 Philippine health statistics. <ext-link ext-link-type="uri" xlink:href="http://www.dohgovph/sites/default/files/publications/2013PHScompressed_0pdf">http://www.dohgovph/sites/default/files/publications/2013PHScompressed_0pdf</ext-link>. Accessed 5 Apr 2018.</mixed-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Wojdyla</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Say</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gulmezoglu</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Van Look</surname>
<given-names>PF</given-names>
</name>
</person-group>
<article-title>WHO analysis of causes of maternal death: a systematic review</article-title>
<source/>Lancet
          <year>2006</year>
<volume>367</volume>
<fpage>1066</fpage>
<lpage>1074</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(06)68397-9</pub-id>
<pub-id pub-id-type="pmid">16581405</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>David-Ona</surname>
<given-names>D</given-names>
</name>
<name>
<surname>De Castro</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Baltazar</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>The distribution of hypertension in the Philippine general hospital after 4 decades (a comparative study)</article-title>
<source/>Acta Med Philipp
          <year>2013</year>
<volume>47</volume>
<issue>3</issue>
<fpage>49</fpage>
<lpage>52</lpage>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amosco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Villar</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Naniong</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>David-Bustamante</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Jose</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Palmes-Saloma</surname>
<given-names>CP</given-names>
</name>
</person-group>
<article-title>VEGF-A and VEGFR1 SNPs associate with preeclampsia in a Philippine population</article-title>
<source/>Clin Exp Hypertens
          <year>2016</year>
<volume>38</volume>
<issue>7</issue>
<fpage>578</fpage>
<lpage>585</lpage>
<pub-id pub-id-type="doi">10.3109/10641963.2016.1174252</pub-id>
<pub-id pub-id-type="pmid">27668980</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hahn</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Ritchie</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions</article-title>
<source/>Bioinformatics
          <year>2003</year>
<volume>19</volume>
<issue>3</issue>
<fpage>376</fpage>
<lpage>382</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btf869</pub-id>
<pub-id pub-id-type="pmid">12584123</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ritchie</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Hahn</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Roodi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Dupont</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Parl</surname>
<given-names>FF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer</article-title>
<source/>Am J Hum Genet
          <year>2001</year>
<volume>69</volume>
<issue>1</issue>
<fpage>138</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="doi">10.1086/321276</pub-id>
<pub-id pub-id-type="pmid">11404819</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edwards</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Velez</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Dudek</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ritchie</surname>
<given-names>MD</given-names>
</name>
</person-group>
<article-title>Exploring the performance of multifactor dimensionality reduction in large scale SNP studies and in the presence of genetic heterogeneity among epistatic disease models</article-title>
<source/>Hum Hered
          <year>2009</year>
<volume>67</volume>
<fpage>183</fpage>
<lpage>192</lpage>
<pub-id pub-id-type="doi">10.1159/000181157</pub-id>
<pub-id pub-id-type="pmid">19077437</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>IH</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>GW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene-gene interactions for asthma and plasma total IgE concentration in Chinese children</article-title>
<source/>J Allergy Clin Immunol
          <year>2006</year>
<volume>117</volume>
<fpage>127</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaci.2005.09.031</pub-id>
<pub-id pub-id-type="pmid">16387595</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>DQ</given-names>
</name>
<name>
<surname>Whitehead</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Menold</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Ashley-Koch</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism</article-title>
<source/>Am J Hum Genet
          <year>2005</year>
<volume>77</volume>
<fpage>377</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="doi">10.1086/433195</pub-id>
<pub-id pub-id-type="pmid">16080114</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Ritchie</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Prince</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dzhura</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Multilocus analysis of hypertension: a hierarchical approach</article-title>
<source/>Hum Hered
          <year>2004</year>
<volume>57</volume>
<fpage>28</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1159/000077387</pub-id>
<pub-id pub-id-type="pmid">15133310</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanada</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yatabe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Midorikawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>JH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Single-nucleotide polymorphisms for diagnosis of salt-sensitive hypertension</article-title>
<source/>Clin Chem
          <year>2006</year>
<volume>52</volume>
<fpage>352</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="doi">10.1373/clinchem.2005.059139</pub-id>
<pub-id pub-id-type="pmid">16439609</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Ritchie</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KU</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>HD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Multifactor-dimensionality reduction shows a two-locus interaction associated with type 2 diabetes mellitus</article-title>
<source/>Diabetologia
          <year>2004</year>
<volume>47</volume>
<fpage>549</fpage>
<lpage>554</lpage>
<pub-id pub-id-type="doi">10.1007/s00125-003-1321-3</pub-id>
<pub-id pub-id-type="pmid">14730379</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whelton</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Carey</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>The 2017 clinical practice guideline for high blood pressure</article-title>
<source/>JAMA
          <year>2017</year>
<volume>318</volume>
<issue>21</issue>
<fpage>2073</fpage>
<lpage>2074</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2017.18209</pub-id>
<pub-id pub-id-type="pmid">29159375</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chobanian</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Bakris</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Cushman</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Izzo</surname>
<given-names>JL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure</article-title>
<source/>Hypertension
          <year>2003</year>
<volume>42</volume>
<fpage>1206</fpage>
<lpage>1252</lpage>
<pub-id pub-id-type="doi">10.1161/01.HYP.0000107251.49515.c2</pub-id>
<pub-id pub-id-type="pmid">14656957</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferreira</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Araújo</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Bezerra</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Duggal</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jeronimo</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Association between ACVR2A and early-onset preeclampsia: replication study in a northeastern Brazilian population</article-title>
<source/>Placenta
          <year>2015</year>
<volume>36</volume>
<issue>2</issue>
<fpage>186</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1016/j.placenta.2014.11.007</pub-id>
<pub-id pub-id-type="pmid">25499008</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roten</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Forsmo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fitzpatrick</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dyer</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Brennecke</surname>
<given-names>SP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study)</article-title>
<source/>Eur J Hum Genet
          <year>2009</year>
<volume>17</volume>
<fpage>250</fpage>
<lpage>257</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2008.158</pub-id>
<pub-id pub-id-type="pmid">18781190</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Renner</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kotschan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Obermayer-Pietsch</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pilger</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels</article-title>
<source/>J Vasc Res
          <year>2000</year>
<volume>37</volume>
<fpage>443</fpage>
<lpage>448</lpage>
<pub-id pub-id-type="doi">10.1159/000054076</pub-id>
<pub-id pub-id-type="pmid">11146397</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shim</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Jun</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Won</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>PR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Vascular endothelial growth factor gene +936 C/T polymorphism is associated with preeclampsia in Korean women</article-title>
<source/>Am J Obstet Gynecol
          <year>2007</year>
<volume>197</volume>
<fpage>271</fpage>
<lpage>274</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajog.2007.06.045</pub-id>
<pub-id pub-id-type="pmid">17826416</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bányász</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Szabo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bokodi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Vannay</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vasarhelyi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Szabo</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic polymorphisms of vascular endothelial growth factor in severe pre-eclampsia</article-title>
<source/>Mol Hum Reprod
          <year>2006</year>
<volume>12</volume>
<fpage>233</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.1093/molehr/gal024</pub-id>
<pub-id pub-id-type="pmid">16517614</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srinivas</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Andrela</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Elovitz</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Allelic variations in angiogenic pathway genes are associated with preeclampsia</article-title>
<source/>Am J Obstet Gynecol
          <year>2010</year>
<volume>202</volume>
<fpage>445.e1</fpage>
<lpage>445.11</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajog.2010.01.040</pub-id>
<pub-id pub-id-type="pmid">20223440</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maynard</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Merchan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mondal</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia</article-title>
<source/>J Clin Invest
          <year>2003</year>
<volume>111</volume>
<fpage>649</fpage>
<lpage>658</lpage>
<pub-id pub-id-type="doi">10.1172/JCI17189</pub-id>
<pub-id pub-id-type="pmid">12618519</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bergmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cudmore</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gruber</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Wittschen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lindenmaier</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model</article-title>
<source/>J Cell Mol Med
          <year>2010</year>
<volume>14</volume>
<fpage>1857</fpage>
<lpage>1867</lpage>
<pub-id pub-id-type="doi">10.1111/j.1582-4934.2009.00820.x</pub-id>
<pub-id pub-id-type="pmid">19538465</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ward</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hata</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jeunemaitre</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Helin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Namikawa</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A molecular variant of angiotensinogen associated with preeclampsia</article-title>
<source/>Nat Genet
          <year>1993</year>
<volume>4</volume>
<fpage>59</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1038/ng0593-59</pub-id>
<pub-id pub-id-type="pmid">8513325</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sethi</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Nordestgaard</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Tybjaerg-Hansen</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis</article-title>
<source/>Arterioscler Thromb Vasc Biol
          <year>2003</year>
<volume>23</volume>
<fpage>1269</fpage>
<lpage>1275</lpage>
<pub-id pub-id-type="doi">10.1161/01.ATV.0000079007.40884.5C</pub-id>
<pub-id pub-id-type="pmid">12805070</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Staines-Urias</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Paez</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Doyle</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dudbridge</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Serrano</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Ioannidis</surname>
<given-names>JP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic association studies in pre-eclampsia: systematic meta-analyses and field synopsis</article-title>
<source/>Int J Epidemiol
          <year>2012</year>
<volume>41</volume>
<fpage>1764</fpage>
<lpage>1775</lpage>
<pub-id pub-id-type="doi">10.1093/ije/dys162</pub-id>
<pub-id pub-id-type="pmid">23132613</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Roten</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Dyer</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>East</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Forsmo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Blangero</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The ERAP2 gene is associated with preeclampsia in Australian and Norwegian populations</article-title>
<source/>Hum Genet
          <year>2009</year>
<volume>126</volume>
<fpage>655</fpage>
<lpage>666</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-009-0714-x</pub-id>
<pub-id pub-id-type="pmid">19578876</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buurma</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Driessen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mooyaart</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schoones</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bruijn</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic variants in pre-eclampsia: a meta-analysis</article-title>
<source/>Pregnancy Hypertens
          <year>2012</year>
<volume>2</volume>
<fpage>204</fpage>
<pub-id pub-id-type="doi">10.1016/j.preghy.2012.04.051</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jääskeläinen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Toivonen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Keski-Nisula</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Paattiniemi</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Helisalmi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Punnonen</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CTLA-4 polymorphism 49A-G is associated with placental abruption and preeclampsia in Finnish women</article-title>
<source/>Clin Chem Lab Med
          <year>2008</year>
<volume>46</volume>
<fpage>169</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="doi">10.1515/CCLM.2008.034</pub-id>
<pub-id pub-id-type="pmid">18076363</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cotran</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Pober</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Cytokine-endothelial interactions in inflammation, immunity, and vascular injury</article-title>
<source/>J Am Soc Nephrol
          <year>1990</year>
<volume>1</volume>
<issue>3</issue>
<fpage>225</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="pmid">2104268</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goddard</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Tromp</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Candidate-gene association study of mothers with preeclampsia and their infants, analyzing 775 SNPs in 190 genes</article-title>
<source/>Hum Hered
          <year>2007</year>
<volume>63</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1159/000097926</pub-id>
<pub-id pub-id-type="pmid">17179726</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<mixed-citation publication-type="other">Fenstad MH, Johnson MP, Roten LT, Aas PA, Forsmo S, Klepper K, et al. Genetic and molecular functional characterization of variants within TNFSF13B, a positional candidate preeclampsia susceptibility gene on 13q. PLoS One. 2010;5(9). 10.1371/journal.pone.0012993.</mixed-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lipoprotein lipase gene is in linkage with blood pressure phenotypes in Chinese pedigrees</article-title>
<source/>Hum Genet
          <year>2004</year>
<volume>115</volume>
<fpage>812</fpage>
<pub-id pub-id-type="doi">10.1007/s00439-004-1108-8</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savvidou</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Vallance</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Nicolaides</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Hingorani</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>Endothelial nitric oxide synthase gene polymorphism and maternal vascular adaptation to pregnancy</article-title>
<source/>Hypertension
          <year>2001</year>
<volume>38</volume>
<fpage>1289</fpage>
<lpage>1293</lpage>
<pub-id pub-id-type="doi">10.1161/hy1201.097305</pub-id>
<pub-id pub-id-type="pmid">11751705</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobashi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ohta</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ebina</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fujimoto</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Endothelial nitric oxide synthase gene (NOS3) variant and hypertension in pregnancy</article-title>
<source/>Am J Med Genet
          <year>2001</year>
<volume>103</volume>
<fpage>241</fpage>
<lpage>244</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1535</pub-id>
<pub-id pub-id-type="pmid">11745998</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eichelberger</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Woodham</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Haeri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Strauss</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Stuebe</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Second-trimester maternal serum paraxanthine, CYP1A2 activity, and the risk of severe preeclampsia</article-title>
<source/>Obstet Gynecol
          <year>2015</year>
<volume>126</volume>
<fpage>725</fpage>
<lpage>730</lpage>
<pub-id pub-id-type="doi">10.1097/AOG.0000000000001041</pub-id>
<pub-id pub-id-type="pmid">26348183</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumru</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aydin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gursu</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Ozcan</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Changes of serum paraoxonase (an HDL-cholesterol-associated lipophilic antioxidant) and arylesterase activities in severe preeclamptic women</article-title>
<source/>Eur J Obstet Gynecol Reprod Biol
          <year>2004</year>
<volume>114</volume>
<fpage>177</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejogrb.2003.10.023</pub-id>
<pub-id pub-id-type="pmid">15140512</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serrato</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marian</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease</article-title>
<source/>J Clin Invest
          <year>1995</year>
<volume>96</volume>
<fpage>3005</fpage>
<lpage>3008</lpage>
<pub-id pub-id-type="doi">10.1172/JCI118373</pub-id>
<pub-id pub-id-type="pmid">8675673</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uzun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Benian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Madazli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Topçuoğlu</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Aydin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Albayrak</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Circulating oxidized low-density lipoprotein and paraoxonase activity in preeclampsia</article-title>
<source/>Gynecol Obstet Investig
          <year>2005</year>
<volume>60</volume>
<fpage>195</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="doi">10.1159/000087205</pub-id>
<pub-id pub-id-type="pmid">16088195</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wheeler</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Keavney</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Watkins</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Danesh</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies</article-title>
<source/>Lancet
          <year>2004</year>
<volume>363</volume>
<issue>9410</issue>
<fpage>689</fpage>
<lpage>695</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(04)15642-0</pub-id>
<pub-id pub-id-type="pmid">15001326</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zusterzeel</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Visser</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hermsen</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Roelofs</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Steegers</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>A polymorphism in the gene for microsomal epoxide hydrolase is associated with pre-eclampsia</article-title>
<source/>J Med Genet
          <year>2001</year>
<volume>38</volume>
<fpage>234</fpage>
<lpage>237</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.38.4.234</pub-id>
<pub-id pub-id-type="pmid">11283205</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laasanen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Romppanen</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Hiltunen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Helisalmi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mannermaa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Punnonen</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Two exonic single nucleotide polymorphisms in the microsomal epoxide hydrolase gene are jointly associated with preeclampsia</article-title>
<source/>Eur J Hum Genet
          <year>2002</year>
<volume>10</volume>
<fpage>569</fpage>
<lpage>573</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ejhg.5200849</pub-id>
<pub-id pub-id-type="pmid">12173035</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zusterzeel</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>De Bruyn</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Knapen</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Merkus</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Steegers</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Glutathione S-transferase isoenzymes in decidua and placenta of preeclamptic pregnancies</article-title>
<source/>Obstet Gynecol
          <year>1999</year>
<volume>94</volume>
<fpage>1033</fpage>
<lpage>1038</lpage>
<pub-id pub-id-type="pmid">10576196</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>York</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Kusanovic</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Eaves</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epistasis between COMT and MTHFR in maternal-fetal dyads increases risk for preeclampsia</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<issue>1</issue>
<fpage>e16681</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0016681</pub-id>
<pub-id pub-id-type="pmid">21304959</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanasaki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Palmsten</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hamano</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia</article-title>
<source/>Nature
          <year>2008</year>
<volume>453</volume>
<fpage>1117</fpage>
<lpage>1121</lpage>
<pub-id pub-id-type="doi">10.1038/nature06951</pub-id>
<pub-id pub-id-type="pmid">18469803</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furness</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Fenech</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Khong</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dekker</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>One-carbon metabolism enzyme polymorphisms and uteroplacental insufficiency</article-title>
<source/>Am J Obstet Gynecol
          <year>2008</year>
<volume>199</volume>
<issue>3</issue>
<fpage>276.e1</fpage>
<lpage>276.e8</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajog.2008.06.020</pub-id>
<pub-id pub-id-type="pmid">18771981</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoque</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Bulbul</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mahal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Islam</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Ferdausi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Serum homocysteine in pre-eclampsia and eclampsia</article-title>
<source/>Bangladesh Med Res Counc Bull
          <year>2008</year>
<volume>34</volume>
<fpage>16</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.3329/bmrcb.v34i1.1165</pub-id>
<pub-id pub-id-type="pmid">18783072</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mignini</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Latthe</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Villar</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kilby</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Carroli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>KS</given-names>
</name>
</person-group>
<article-title>Mapping the theories of preeclampsia: the role of homocysteine</article-title>
<source/>Obstet Gynecol
          <year>2005</year>
<volume>105</volume>
<fpage>411</fpage>
<lpage>425</lpage>
<pub-id pub-id-type="doi">10.1097/01.AOG.0000151117.52952.b6</pub-id>
<pub-id pub-id-type="pmid">15684173</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sorensen</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Malinow</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>King</surname>
<given-names>IB</given-names>
</name>
<name>
<surname>Luthy</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Elevated second-trimester serum homocysteine levels and subsequent risk of preeclampsia</article-title>
<source/>Gynecol Obstet Investig
          <year>1999</year>
<volume>48</volume>
<fpage>98</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1159/000010148</pub-id>
<pub-id pub-id-type="pmid">10460999</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Felder</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Sanada</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>PY</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>G protein-coupled receptor kinase 4 gene variants in human essential hypertension</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2002</year>
<volume>99</volume>
<fpage>3872</fpage>
<lpage>3877</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.062694599</pub-id>
<pub-id pub-id-type="pmid">11904438</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Pooled analyses of the associations of polymorphisms in the GRK4 and EMILIN1 genes with hypertension risk</article-title>
<source/>Int J Med Sci
          <year>2012</year>
<volume>9</volume>
<fpage>274</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="doi">10.7150/ijms.4171</pub-id>
<pub-id pub-id-type="pmid">22639547</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Premont</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Macrae</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Stoffel</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pitcher</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Ambrose</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of the G protein coupled receptor kinase GRK4. Identification of four splice variants</article-title>
<source/>J Biol Chem
          <year>1996</year>
<volume>271</volume>
<fpage>6403</fpage>
<lpage>6410</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.271.11.6403</pub-id>
<pub-id pub-id-type="pmid">8626439</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>ZQ</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>LN</given-names>
</name>
</person-group>
<article-title>Association between GRK4 and DRD1 gene polymorphisms and hypertension: a meta-analysis</article-title>
<source/>Clin Interv Aging
          <year>2015</year>
<volume>11</volume>
<fpage>17</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.2147/CIA.S94510</pub-id>
<pub-id pub-id-type="pmid">26730182</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>StataCorp</collab>
</person-group>
<source/>Stata statistical software: release 14
          <year>2015</year>
<publisher-loc>College Station</publisher-loc>
<publisher-name>StataCorp LP</publisher-name>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gui</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hillege</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>van der Harst</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A simple and computationally efficient approach to multifactor dimensionality reduction analysis of gene-gene interactions for quantitative traits</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<issue>6</issue>
<fpage>e66545</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0066545</pub-id>
<pub-id pub-id-type="pmid">23805232</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kiralis</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>ViSEN: methodology and software for visualization of statistical epistasis networks</article-title>
<source/>Genet Epidemiol
          <year>2013</year>
<volume>37</volume>
<fpage>283</fpage>
<lpage>285</lpage>
<pub-id pub-id-type="doi">10.1002/gepi.21718</pub-id>
<pub-id pub-id-type="pmid">23468157</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muttukrishna</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Child</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Groome</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Ledger</surname>
<given-names>WL</given-names>
</name>
</person-group>
<article-title>Source of circulating levels of inhibin a, pro alpha C- containing inhibins and activin a in early pregnancy</article-title>
<source/>Hum Reprod
          <year>1997</year>
<volume>12</volume>
<fpage>1089</fpage>
<lpage>1093</lpage>
<pub-id pub-id-type="doi">10.1093/humrep/12.5.1089</pub-id>
<pub-id pub-id-type="pmid">9194671</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arngrímsson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sigurardttir</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Frigge</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Bjarnadóttir</surname>
<given-names>RI</given-names>
</name>
<name>
<surname>Jónsson</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Stefánsson</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A genome-wide scan reveals a maternal susceptibility locus for preeclampsia on chromosome 2p13</article-title>
<source/>Hum Mol Genet
          <year>1999</year>
<volume>8</volume>
<fpage>1799</fpage>
<lpage>1805</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/8.9.1799</pub-id>
<pub-id pub-id-type="pmid">10441346</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laivuori</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lahermo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ollikainen</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Widen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Haiva-Mallinen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sundström</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families</article-title>
<source/>Am J Hum Genet
          <year>2003</year>
<volume>72</volume>
<fpage>168</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="doi">10.1086/345311</pub-id>
<pub-id pub-id-type="pmid">12474145</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moses</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Lade</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wilton</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Grehan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Freed</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2</article-title>
<source/>Am J Hum Genet
          <year>2000</year>
<volume>67</volume>
<fpage>1581</fpage>
<lpage>1585</lpage>
<pub-id pub-id-type="doi">10.1086/316888</pub-id>
<pub-id pub-id-type="pmid">11035632</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moses</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Fitzpatrick</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Freed</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Dyer</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Forrest</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Objective prioritization of positional candidate genes at a quantitative trait locus for pre-eclampsia on 2q22</article-title>
<source/>Mol Hum Reprod
          <year>2006</year>
<volume>12</volume>
<fpage>505</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="doi">10.1093/molehr/gal056</pub-id>
<pub-id pub-id-type="pmid">16809377</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ritchie</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Hahn</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity</article-title>
<source/>Genet Epidemiol
          <year>2003</year>
<volume>24</volume>
<fpage>150</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1002/gepi.10218</pub-id>
<pub-id pub-id-type="pmid">12548676</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Association between thrombophilia gene polymorphisms and preeclampsia: a Meta-analysis</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<issue>6</issue>
<fpage>e100789</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0100789</pub-id>
<pub-id pub-id-type="pmid">24967675</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhi</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Associations of MTHFR gene polymorphisms with hypertension and hypertension in pregnancy: a meta analysis from 114 studies with 15411 cases and 21970 controls</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<issue>2</issue>
<fpage>e87497</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0087497</pub-id>
<pub-id pub-id-type="pmid">24505291</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luizon</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Palei</surname>
<given-names>ACT</given-names>
</name>
<name>
<surname>Sandrim</surname>
<given-names>VC</given-names>
</name>
</person-group>
<article-title>Polymorphisms and haplotypes in candidate genes related to angiogenesis and endothelial dysfunction in preeclampsia</article-title>
<source/>J Pregnancy
          <year>2012</year>
<volume>2012</volume>
<fpage>914704</fpage>
<pub-id pub-id-type="doi">10.1155/2012/914704</pub-id>
<pub-id pub-id-type="pmid">22570788</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>